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hypertriglyceridemia (≥ 205 mg/dL) benefited the
most.5 Clofibrate is no longer used because of an
unexplained increase in deaths in the WHO
Cooperative Trial.6 To date, outcomes in fenofibrate
trials have only focused on surrogate markers and
not long-term clinical outcomes.
RECOMMENDATIONS FROM OTHERS The rec-
ommendations of the Third Report of the National
Cholesterol Education Program7 (NCEP, Adult
Treatment Panel III) are in the table. This report is an
excellent source of additional information
(http://www.nhlbi.nih.gov/guidelines/cholesterol/at
p3xsum.pdf). 
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What levels of cholesterol should 
be treated for primary prevention?
EVIDENCE-BASED ANSWER The levels of choles-
terol that should be treated for primary prevention
are based on low-density lipoprotein cholesterol
(LDL-C) levels of > 100 mg/dL to > 190 mg/dL and
vary according to whether the patient’s risk is high,
moderate, or low. See the table to estimate risk.
Grade of recommendation for medication indica-
tions: A (on the basis of high-quality randomized
controlled trials). Grade of recommendation for
lifestyle indications: B (on the basis of extrapolations
from randomized controlled trials).
EVIDENCE SUMMARY Statins are the most effec-
tive at reducing LDL-C and the associated cardiovas-
cular risk. The 5-year West of Scotland study
(WOSCOPS) showed that a 26% reduction in LDL-C
(from a mean of 192 to 142 mg/dL) using pravastatin
40 mg per day reduced the risk of either nonfatal
myocardial infarction (MI) or coronary heart disease
(CHD) death (number needed to treat [NNT] = 42;
relative risk [RR] = 31; 95% confidence interval [CI],17
- 43).1 This trial enrolled middle-aged men with an
LDL-C level > 155 mg/dL without a history of prior
MI, although subjects with stable angina (5% of the
participants) were still eligible. Similar reductions
were seen in cardiovascular death and in all-cause
death (RR = 22; 95% CI = 0 - 40). Lovastatin reduced
the risk of a first major acute coronary event (NNT =
24) in the 5-year AFCAPS/TexCAPS trial that enrolled
5608 men and 997 women with below-average high-
density lipoprotein cholesterol (HDL-C) (men, 36
mg/dL; women, 40 mg/dL) without signs or symp-
toms of CHD.2 LDL-C was lowered 25% (from a
mean of 156 to 115 mg/dL).  Unpublished results
suggest that simvastatin may have a similar effect.
Primary prevention data are still lacking for atorvastatin
and fluvastatin.
The 7-year Lipid Research Clinics Coronary
Prevention Trial (LRC-CPPT) documented a reduction
in CHD death and/or nonfatal MI (NNT = 59) with a
12.6% reduction in LDL-C with the use of cholestyra-
mine, a bile acid resin, 24 g per day.3
Results of studies of the fibric acid derivatives are
mixed. Subjects taking gemfibrozil 1200 mg per day
in the 5-year Helsinki Heart Study had fewer coro-
nary events compared with those taking a placebo
(NNT = 71).4 Subsequent analysis suggests that
patients with a high LDL-C/HDL-C ratio (> 5) plus
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Adult treatment recommendations from NCEP, 
Adult Treatment Panel III
LDL-C goal*
at which to consider
Risk category LDL-C level medication 
Coronary heart disease < 100 mg/dL ≥ 130 mg/dL;
risk equivalents ≥ 100-129 mg/dL
optional
2 or more major risk factors† < 130 mg/dL 10-year risk‡  
10-20%: ≥ 130 mg/dL;
10-year risk‡ < 10%:
≥ 160 mg/dL
0 or 1 major risk factor† < 160 mg/dL ≥ 190 mg/dL;
160-190 mg/dL 
optional
NOTE: CHD risk equivalents include symptomatic carotid artery disease, peripheral arterial dis-
ease, abdominal aortic aneurysm, diabetes, and a 10-year risk of > 20% (see ‡ below).  The cut-
off points for therapy for patients with clinical CHD are the same as for CHD risk equivalents. 
* Initiate therapeutic lifestyle changes above these levels.
†Major risk factors include cigarette smoking, hypertension, HDL < 40 mg/dL, family history of
premature CHD (CHD in first-degree male relative < 55 y; CHD in first-degree female relative 
< 65 y), age (men ≥ 45 y, women ≥ 55 y). 
‡To calculate 10-year risk, use the Framingham Tables, available at
http://www.nhlbi.nih.gov/guidelines/cholesterol/risk_tbl.htm. 
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